Abbott Expands its Weesp Manufacturing Site in the Netherlands

“Investment contributes to the further development of innovative healthcare in the Netherlands and beyond”

Abbott officially opened a new building at its manufacturing site in Weesp, the Netherlands, on Wednesday 25 July 2018 . The new building expands Abbott’s production of dydrogesterone, a medicine used to treat progesterone insufficiency in women. Representing an overall investment of $80 million, the new building features the same modern technology as the existing building and will increase Abbott’s total production capacity by 60 percent. Now totalling an overall production capacity of more than 1,5 billion tablets per year, distributed to more than 100 countries in the world, Abbott remains the leading manufacturer of dydrogesterone worldwide.

“Foreign companies and their investments are important for our country,” says Minister Wiebes of Economic Affairs & Climate Policy. “Thanks to them, 1.4 million Dutch people have a job directly or indirectly. Therefore, I am very pleased that Abbott has opted for an expansion of its medicines production in the Netherlands. This investment not only underlines the long-term relationship between the Netherlands and Abbott, it also contributes to the further development of innovative healthcare in the Netherlands and beyond.”

Life-saving medicines

As a result of the growing demand for quality medicines such as Abbott’s dydrogesterone for women’s health, Abbott is continually investing to increase its production capacity in Weesp.

“We see an increasing demand for dydrogesterone in fast-growing countries like China, India or Russia,” says Sieneke Bult, site director for Abbott’s plant in Weesp. “One of the medicines that we produce here in Weesp with dydrogesterone is a life-saving one. It has already had a lasting impact on the lives of millions of women worldwide by helping them get and stay pregnant.”

Reducing CO2 emission

Thanks to an investment in green hydropower energy, the site reduced its CO2 emission by over 50% in 2017 and its vast location has an ecosystem that houses 74 bird species.

Besides dydrogestrone, Abbott manufactures two other products in Weesp: Duphalac (lactulose) and Influvac (influenza vaccine). In 2015, Abbott completed the building of a new influenza factory, which increased its production capacity from 34 million doses to 54 million doses.

About Abbott

At Abbott, we’re committed to helping you live your best possible life through the power of health. For 125 years, we’ve brought new products and technologies to the world—in nutrition, diagnostics, medical devices and branded generic pharmaceuticals—that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

26 July 2018

Get In Touch

LDN

NFIA UK & Ireland

Embassy of the Kingdom of the Netherlands
38 Hyde Park Gate
London SW7 5DP
United Kingdom
T. +44 207 590 3286
E. info@nfia.co.uk


Ties Elzinga

Executive Director NFIA UK & Ireland +44 (0) 207 5903 286

LinkedIn VCF

Arjen Leemburg

Senior Project Manager NFIA UK & Ireland +44 (0)207 5903 286

LinkedIn VCF
Skip to toolbar